Skip to main content
TipRanks
Go Ultimate75% OFF

Tonix Pharma (TPM0) AI Stock Analysis

9 Followers
DE:TPM0

Tonix Pharma

(Frankfurt:TPM0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Rapid Revenue Growth and High Gross MarginTTM revenue rose from $13.1M in 2025 to $43.0M, while gross margin reached about 86.9%. This combination shows TONMYA-driven commercialization is adding meaningful scale and leaves substantial gross profit per dollar of sales, creating a platform for future operating leverage if growth persists.
Negative Factors
Severe Operating Losses and Cash BurnTTM EBIT was -$187.8M, operating cash flow -$165.3M, and free cash flow -$170.0M. Persistent losses at this scale consume resources despite revenue growth, reduce internally funded investment capacity, and make continued external financing important for sustaining development and commercialization.

Tonix Pharma (TPM0) vs. iShares MSCI Germany ETF (EWG)

-100%-75%-50%-25%0%25%50%DE:TPM0-79.29%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 49.55M
Dividend Yield
―
Average Volume (3M)
42
Price to Earnings (P/E)
-0.2
Beta (1Y)
0.49
Revenue Growth
299.05%
EPS Growth
98.86%
Country
Germany
Employees
142
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Tonix Pharma Business Overview & Revenue Model

Company Description

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and dia...

Tonix Pharma Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:-39.27%|Next Earnings Date:May 13, 2024
Earnings Call SentimentPositive

The call was predominantly positive, led by strong TONMYA sales and prescription growth, improving payer coverage, rising refills, expanded commercial reach, and continued progress across the clinical pipeline. The main challenges were the Dr. Reddy's Paragraph IV patent challenge, materially higher operating expenses, a declining cash balance, uncertainty around some clinical timelines, and the regulatory impasse for TNX-1300.

Positive Updates

TONMYA Sales Growth
Third-quarter TONMYA net sales were approximately $15 million, increasing 37% quarter-over-quarter. Growth was supported by previously signed payer agreements, more favorable gross-to-net adjustments than expected, and execution of the launch strategy.

Negative Updates

Generic Patent Challenge
On October 1, 2026, Tonix received notice that Dr. Reddy's Laboratories had filed an ANDA Paragraph IV patent certification for TONMYA. Management said it is in the Hatch-Waxman process and will vigorously defend its intellectual property, but did not provide details on the ongoing litigation.

Company Guidance

Management expects TONMYA’s positive trends to continue into the fourth quarter, with a larger sales force and growing sales, and believes it is “well positioned for a strong fourth quarter and 2027”; the 150-person sales force is targeting roughly 70% of approximately 25,000 HCPs who diagnose and treat fibromyalgia, while coverage reaches approximately 53% of covered lives in the U.S. and is expected to continue expanding. The company expects gross to net fluctuations early in the launch, continued progress in coverage, continued improvement on copay buydowns and approval rates, and “consistent growth” through Q4 through 2027. For TNX-4800, the adaptive Phase II TRAIL study is expected to begin in the first quarter of 2027, enroll approximately 3,300 adults over 2 Lyme seasons, start with a lead-in cohort of approximately 500 participants in the first quarter of 2027, and enroll the balance of the efficacy cohort in the 2028 Lyme season; the company expects safety clearance by the end of the second quarter or early in the third quarter, and expects to begin enrolling in the Phase II study in the first half of 2027. An investigator-initiated Phase II study of TNX-1500 is expected to begin in the first quarter of 2027 at Massachusetts General Hospital, enroll five patients, and has a primary endpoint of 18 months with interim looks at earlier time points. The company expects its cash resources and net proceeds raised from the equity offering after quarter end to meet operating and capital expenditure requirements into early third quarter of 2027, has guided to runway into Q3 of next year, is monitoring expenses and focusing on key programs, and is not yet guiding to HORIZON enrollment completion or top-line timing, although it is hoping to enroll it quickly and provide guidance hopefully sometime soon.

Tonix Pharma Risk Analysis

Tonix Pharma disclosed 71 risk factors in its most recent earnings report. Tonix Pharma reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.Our use of artificial intelligence could adversely affect our business, financial condition and results of operationsQ3, 2026
2.We have received a paragraph IV certification notice from a generic manufacturer seeking approval to market a generic version of TONMYA prior to the expiration of our Orange Book-listed patents. If generic manufacturers are successful in their use of litigation or regulatory means to obtain approval for generic versions of TONMYA, our revenue and results of operations would be adversely affected.Q3, 2026

Tonix Pharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:TPM0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PLXPLX77Outperform$258.02M11.1430.74%―36.96%266.67%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IPHAIPHA50Neutral$110.92M-1.62152.56%―-24.21%1.17%
FATEFATE42Neutral$122.78M-0.89-73.92%―-33.45%21.90%
AVTXAVTX38Underperform$390.31M-2.34-34.21%―-69.27%66.84%

* Healthcare Sector Average

Performance Comparison

0%100%DE:TPM0PLXFATEAVTXIPHADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:TPM0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:TPM0Tonix Pharmaceuticals2.46-9.84-79.96%
PLXProtalix Biotherapeutics2.901.1565.71%
FATEFate Therapeutics Inc0.92-0.16-14.91%
AVTXAvalo Therapeutics, Inc.6.76-11.24-62.44%
IPHAInnate Pharma SA Sponsored ADR0.86-0.95-52.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.